Abstract
In experiments to determine susceptibility of primary human mammary cells to infection with HIV type 1 as part of HIV breast milk pathogenesis studies,1 our intentions were to block HIV receptor binding, halt viral replication, or prevent endocytosis using pharmaceutical preparations. For the purposes of these studies, we obtained human mammary epithelial cells (MECs) from consenting reduction mammoplasty patients, digested the tissue, and enriched for BerEp4+ MECs per published protocols.2–6 Our initial series of experiments were conducted by culturing enriched MECs on tissue culture plates or on transwell membranes (BD/Falcon, Franklin Lakes, NJ).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.